The association of psychedelic use and opioid use disorders among illicit users in the United States
Open Access
- 14 February 2017
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 31 (5) , 606-613
Abstract
Preliminary studies show psychedelic compounds administered with psychotherapy are potentially effective and durable substance misuse interventions. However, little is known about the association between psychedelic use and substance misuse in the general population. This study investigated the association between psychedelic use and past year opioid use disorders within illicit opioid users. While controlling for socio-demographic covariates and the use of other substances, the relationship between classic psychedelic use and past year opioid use disorders was analyzed within 44,000 illicit opioid users who completed the National Survey on Drug Use and Health from 2008 to 2013. Among respondents with a history of illicit opioid use, psychedelic drug use is associated with 27% reduced risk of past year opioid dependence (weighted risk ratio = 0.73 (0.60–0.89) p = 0.002) and 40% reduced risk of past year opioid abuse (weighted risk ratio = 0.60 (0.41–0.86) p = 0.006). Other than marijuana use, which was associated with 55% reduced risk of past year opioid abuse (weighted risk ratio = 0.45 (0.30–0.66) p < 0.001), no other illicit drug was associated with reduced risk of past year opioid dependence or abuse. Experience with psychedelic drugs is associated with decreased risk of opioid abuse and dependence. Conversely, other illicit drug use history is largely associated with increased risk of opioid abuse and dependence. These findings suggest that psychedelics are associated with positive psychological characteristics and are consistent with prior reports suggesting efficacy in treatment of substance use disorders.Keywords
This publication has 46 references indexed in Scilit:
- A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)Journal of Psychopharmacology, 2012
- Oral naltrexone maintenance treatment for opioid dependence2011
- Effects of Direct- and Indirect-Acting Serotonin Receptor Agonists on the Antinociceptive and Discriminative Stimulus Effects of Morphine in Rhesus MonkeysNeuropsychopharmacology, 2011
- The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot studyJournal of Psychopharmacology, 2010
- Methadone maintenance therapy versus no opioid replacement therapy for opioid dependenceCochrane Database of Systematic Reviews, 2009
- Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: Results from two national surveysAddictive Behaviors, 2008
- Human hallucinogen research: guidelines for safetyJournal of Psychopharmacology, 2008
- Antidepressant Agents for the Treatment of Chronic Pain and DepressionPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- Values and Beliefs of Psychedelic Drug Users: A Cross-Cultural StudyJournal of Psychoactive Drugs, 2006
- The Use of Hallucinogens in the Treatment of AddictionAddiction Research, 1996